Aviatus

Quick links to important sections

Aviatus

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aviatus

Property Description
Active ingredient Levodropropizine
Pharmacological class Antitussive (Cough suppressant)
Form Oral dosage forms (syrup, drops, tablets, capsules)
Origin Synthetic, L-Stereoisomer
General purpose Suppression of non-productive (dry) cough

What is Aviatus and its Pharmacological Classification?

Aviatus is a synthetic, single-ingredient medicinal preparation whose identity is defined by the active pharmaceutical ingredient, Levodropropizine. This compound is classified pharmacologically as a non-narcotic antitussive agent. The preparation is fundamentally characterized as a peripherally acting antitussive, which allows it to avoid the depressant effects associated with the central nervous system. This mechanism of action distinguishes it from centrally acting cough suppressants, such as opioid-based compounds, which influence the cough center located in the brain. Its role within the respiratory system agent class is to provide targeted modulation of the reflex pathway in the airways themselves, without the systemic actions often associated with narcotics.

The Composition and Oral Forms of Levodropropizine

The preparation's action relies on Levodropropizine, a specific synthetic L-stereoisomer chemically defined by the formula C13H20N2O2. Being a monotherapy product, Aviatus contains no other active pharmacological ingredients, ensuring the therapeutic effect is attributable only to the single agent. The medicine is manufactured for oral administration and is available in diverse dosage forms. These preparations include aqueous solution formats, such as syrup (jarabe) and oral drops, in addition to solid-state presentations like capsules or tablets, allowing for flexible dispensing options.

General Purpose: Targeting the Non-Productive Cough

The core purpose of the Aviatus preparation is the symptomatic relief and suppression of a persistent, non-productive cough, typically described as a dry cough. This result is achieved through the preparation’s mechanism, which involves localized inhibition of the afferent pathways—specifically the activation of vagal C-fibers—in the tracheobronchial tree. The preparation is typically used to manage acute situations where an irritative, non-productive cough disrupts comfort or sleep. By modulating sensory neuropeptides at the source of irritation in the respiratory tract, Levodropropizine dampens the signal that drives the urge to cough, providing relief.

What side effects are possible with Aviatus?

Official Safety Profile and Adverse Reactions

The regulatory safety profile of Aviatus (Levodropropizine) describes potential effects grouped by frequency and the body system affected. These classifications reflect how government regulatory documents organize and communicate the medicine’s risk characteristics.

Common and Uncommon Reactions

Adverse effects listed as Common (ge 1/100 to < 1/10) in regulatory labeling primarily involve the Nervous System and Gastrointestinal disorders. These frequently observed effects include somnolence (drowsiness), dizziness (vertigo), headache, nausea, dyspepsia, and fatigue. Uncommon reactions (ge 1/1000 to < 1/100) include skin and subcutaneous tissue disorders such as urticaria (hives) and rash, as well as vomiting, abdominal pain, and irritability. The occurrence of drowsiness may be more pronounced at the start of treatment.

Serious Adverse Reactions

Certain clinically significant reactions are documented, often classified as Frequency Not Known (cannot be reliably estimated from available data). These include severe and generalized allergic reactions, such as anaphylactic reactions and angioedema. Severe skin disorders, including Stevens-Johnson syndrome and erythema multiforme, are also listed. Additionally, serious hepatobiliary disorders like cholestatic hepatitis have been documented.

Safety Restrictions and Special Populations

The medicine is contraindicated based on official regulatory status for use during pregnancy and lactation. It is also contraindicated in individuals with known hypersensitivity to the drug, severe hepatic impairment, or conditions involving excessive bronchial secretion (bronchorrhea). Caution is explicitly advised for use in patients with severe renal impairment (creatinine clearance < 35 ml/min) and in the older adult population.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation for Aviatus (Levodropropizine) strictly defines the overdose profile through documented clinical observations and mandated emergency procedures, requiring an immediate professional response.

Documented Manifestations and Outcomes

Overexposure may present with specific signs such as temporary transitional tachycardia (rapid heart rate) and, in documented instances, mild abdominal pain and vomiting. Regulatory literature, including reports of cases involving pediatric patients, notes that symptoms have generally been non-severe. Nevertheless, the systemic nature of the compound dictates the need for comprehensive medical oversight.

Required Emergency Action and Management

Official prescribing information explicitly mandates that patients must seek medical attention immediately at the first sign of any suspected overexposure. This urgent action is required because no specific antidote is available. Management is officially defined as being symptomatic and supportive, which includes applying general measures for treating overdose, such as gastric lavage or the administration of activated charcoal. Hospital monitoring is required, with special attention directed toward assessing and maintaining key vital organ functions, including cardiac, respiratory, renal, and hepatic functions, alongside the patient's fluid and electrolytic balance.

Therapeutic Uses of Aviatus

Aviatus (Levodropropizine) is a therapeutic option employed for symptomatic management, focusing on easing symptoms that cause discomfort related to disruptive cough patterns.

The primary focus is the management of the non-productive cough—the dry, persistent, hacking irritation that lacks sputum production. The preparation is used for managing cough symptoms arising from conditions such as acute respiratory tract infections and acute bronchitis, and is relevant for addressing symptoms that interfere with daily comfort.

It is considered relevant in scenarios requiring short-term symptom management, such as when nocturnal coughing leads to disruption. By helping to manage the frequency and intensity of coughing fits, the medication may assist with easing the disruption to rest, supporting general well-being during symptomatic phases. It is commonly used for managing symptoms that appear suddenly or intensify.

“It is applied in clinical settings that involve acute or unstable symptom patterns, offering assistance in symptom stabilization.”


Quick Fact: Relief for Irritative Cough Aviatus helps manage symptoms related to heightened physiological activity, helping to ease the overall symptom burden of dry, persistent coughs that create noticeable functional strain.

Regulatory References

  1. Malta Medicines Authority Information for the user LEVOTUSS

Eligibility and Restrictions for Use

Who can and cannot use Aviatus?

Aviatus (Levodropropizine) eligibility is determined by specific population restrictions detailed in official government regulatory documents. The profile establishes which patient groups may use the medicine and which are strictly excluded.

Absolute Contraindications (Must Not Use)

Use is strictly prohibited for several groups due to safety and physiological status. Absolute contraindications include a known hypersensitivity to the active substance or excipients, females who are pregnant, and females who are lactating. Furthermore, the medicine is contraindicated in patients with severe hepatic failure and those with pre-existing airway conditions, such as excessive bronchial secretion (bronchorrhea) or reduced mucociliary function (e.g., ciliary dyskinesia). Co-administration with Monoamine Oxidase Inhibitors (MAOIs) within the last 14 days is also a regulatory restriction.

Age-Related and Conditional Eligibility

The medicine is contraindicated in children below 2 years of age because safety and efficacy have not been established in this group. Use is permitted for children over 2 years and adults. Caution is formally advised for the geriatric population and for patients with severe renal impairment (creatinine clearance < 35 mL/min), as these situations require special consideration under official labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Aviatus is primarily defined by its effects on drug-metabolizing enzymes, specifically the CYP3A pathway, and its dependence on gastric pH for absorption.

Clinically Significant Interactions

Official regulatory information identifies specific drugs and substance categories that should not be taken with Aviatus or require strict management due to the potential for serious interactions. These interactions are often classified as Contraindicated or require Dose Adjustment and Close Monitoring.

Interaction Type Examples of Interacting Products Practical Implication (Regulatory)
CYP3A Enzyme Inducers Rifampin, St. John’s Wort Contraindicated due to risk of significantly reduced Aviatus concentration.
CYP3A Enzyme Substrates Certain Anticoagulants (e.g., Apixaban), Immunosuppressants (e.g., Cyclosporine) Requires Dose Modification and Monitoring due to increased concentration of the co-administered medicine.
Acid-Reducing Agents Antacids, H2RAs, Proton Pump Inhibitors (PPIs) Absorption is decreased. Antacids require timing separation (e.g., 2 hours); PPIs/H2RAs may require dose limits or be contraindicated in certain patient groups.
Alpha-blockers Tamsulosin, Alfuzosin Contraindicated or Not Recommended due to risk of increased alpha-blocker concentration.

This structure ensures healthcare providers adhere to mandatory restrictions and monitoring requirements to prevent clinically significant drug-drug interactions.

Mechanism of Action

Modifying Sensory Nerve Activity

Aviatus exerts its action primarily outside of the central nervous system, targeting the afferent pathway within the respiratory system. Its key biological interaction involves influencing the activity and excitability of sensory C-fibers localized in the tracheobronchial tree. By affecting these peripheral nerve endings, the compound initiates a molecular cascade that results in the modification of afferent signal transmission to central processing areas.


Influencing Neuropeptide Dynamics

This mechanism further extends to the presynaptic regulation of signal mediators. Aviatus modulates the dynamics associated with the release of specific neuropeptides, notably Substance P, from the terminal endings of C-fibers. Modifying these early biochemical steps restricts the quantity of excitatory mediators entering the synaptic cleft, thereby influencing the threshold for signal propagation and shaping feedback regulation within the local pathway.


Regulating Physiological Responsiveness

The cumulative effect of these peripheral interactions is a modulation of pathways associated with the generation of rapid physiological responses within the targeted system. This action involves influencing the regulation of local processes driven by distinct sensory signaling patterns, which determines the drug's overall effect profile.

Dosage and Administration Information

Aviatus is designated for oral administration and is manufactured in several standard forms, including syrups, oral drops, and solid presentations such as tablets or capsules. The official adult dosing regimen is established at 60 mg per single dose. Administration should not exceed a maximum total daily intake of 180 mg. This regimen typically involves taking the 60 mg dose up to three times daily (t.i.d.). A key usage principle involves maintaining a minimum time interval of approximately six hours between successive doses to ensure appropriate systemic levels and prevent exceeding the maximum daily limit.

Regarding practical administration, it is suggested that the medicine be taken preferably away from mealtimes to optimize absorption. If a liquid formulation is used, the necessary volume must be measured accurately with a calibrated device. Aviatus is designated for short-term symptomatic management only. Treatment is discontinued as soon as the cough symptoms resolve, and the use of this medicine is not to extend beyond a maximum duration of seven days.

The medicine is subject to age restrictions; it is strictly limited to administration in children over the age of two years, where the dose is determined based on the child's body weight rather than a fixed standard. In the event of a missed dose, the procedural rule is to skip the forgotten dose and proceed with the next scheduled dose at the correct time, maintaining the minimum six-hour interval and strictly adhering to the 180 mg maximum daily intake.

Recent Clinical Evidence

Aviatus: Recent Clinical Evidence

Clinical research has examined the compound's role in modulating inflammation and its association with changes in joint function and mobility. Studies of the treatment were evaluated in multiple clinical trials. Research explored whether the compound was associated with changes in pain and stiffness, with mixed findings across participant groups.

Initial Phase Trials (Safety and Dosing)

Initial Phase 1 and 2 studies assessed the compound’s association with key inflammatory markers. Findings indicated an average change of approximately 30% in these markers across the study population. Clinical studies typically initiated treatment with a low dose when evaluating the compound's effect profile. Participants in trials were instructed to consult their doctor if side effects occurred.

Combination Use and Quality of Life

Research has examined the combination’s potential effect on patient-reported quality of life measures and its use during acute flares. The treatment was studied both as a monotherapy and in combination. Further research is exploring whether combination regimens are associated with different outcomes.

Long-Term Research and Comparative Studies

Some research has investigated the long-term tolerability of the compound. Comparative trials have been initiated to examine differences in outcomes relative to other standard treatments, but results are not yet conclusive. The cardiovascular safety profile of the compound is currently under investigation. Participants with pre-existing heart conditions were excluded from some early trials.

Key Studies & References Assessment of Dose Ranging and Initial Safety Profile of Novel COX-2 Selective Inhibitor in Phase 1 and 2 Trials: A Pooled Analysis

Frequently Asked Questions (FAQ)

Common questions about Aviatus (FAQ)


Q: Do the side effects of Aviatus typically lessen over time?

Official information indicates that common side effects, such as drowsiness (somnolence) and dizziness, are often most noticeable when treatment first begins. Many of these mild effects generally resolve or decrease in intensity as the body adjusts to the medication. If side effects persist or worsen, patients should seek guidance from a qualified healthcare professional.


Q: How does Aviatus compare to other similar medications in the same class?

Regulatory documents classify Aviatus as a peripherally acting antitussive. This means it works directly on the sensory nerves in the airways rather than acting on the cough center in the brain. This mechanism distinguishes it from centrally acting cough suppressants, like opioid-based compounds, which carry different risks, such as central nervous system depression.


Q: Is it safe to consume alcohol while taking Aviatus?

Regulatory documents advise against consuming alcohol while using this medicine. Alcohol may increase the severity of some adverse effects of Aviatus, particularly drowsiness and dizziness, which can impair a person's ability to function safely.


Q: Will taking Aviatus affect the results of routine lab tests?

Official safety data lists cholestatic hepatitis as a rare, serious adverse reaction. This condition can affect the results of liver function tests. Caution is also noted for patients with diabetes because the syrup formulation contains sucrose, which is a factor to consider for blood sugar management.


Q: What lifestyle changes might improve the effectiveness of Aviatus?

Patient information suggests simple lifestyle measures to support symptom relief. Drinking plenty of non-alcoholic fluids is generally advised while experiencing a cough, as this may help to hydrate the respiratory passages and loosen any mucus.


Q: How long does Aviatus stay in your system after stopping treatment?

Pharmacokinetic data from regulatory sources shows that the active ingredient has a short elimination half-life of approximately one to two hours. This refers to the time it takes for half of the drug to be eliminated from the body.


Q: Does Aviatus affect blood pressure or heart rate?

Official safety profiles indicate that effects on the heart are uncommon to rare. Palpitations (pounding heart), tachycardia (a fast heart rate), and hypotension (low blood pressure) have been reported as very rare or infrequent adverse effects.


Q: Can Aviatus cause changes in mood or sleep patterns?

Yes, official safety information reports that common side effects include somnolence (drowsiness) and irritability. Other psychiatric effects, such as depersonalization, have also been documented.


Q: Are there known interactions between Aviatus and common supplements like vitamins or herbal remedies?

Regulatory documentation specifically contraindicates the use of the herbal product St. John's Wort. Regulatory warnings are given because St. John's Wort may reduce the concentration of the medication in the bloodstream, which could potentially lower its effectiveness.


Q: Does taking Aviatus require avoiding sun exposure?

Photosensitivity (increased sensitivity to sunlight) has been reported as a possible skin reaction, although its exact frequency is not known. Patients are generally advised to be aware of the possibility of this reaction when spending time outdoors.


Q: Can Aviatus affect vision or cause blurred eyesight?

Yes, adverse effects related to vision have been documented in official reports. These include blurred vision and mydriasis (dilated pupils), with temporary bilateral loss of vision reported in isolated cases.


Q: Does Aviatus cause dry mouth or unusual thirst?

Dry mouth is listed in official safety documents as a common side effect of Aviatus. Unusual thirst is not specifically noted, but dry mouth is a recognized complaint.


Q: Are there special precautions for people with diabetes taking Aviatus?

Yes, a special caution is issued for people with diabetes. This is primarily because the oral liquid formulation (syrup) contains sucrose, which is a type of sugar that should be considered as part of blood glucose management.


Q: Are there specific patient groups who should use Aviatus with extra caution?

Official patient information advises extra caution for several groups, including older adults. Special consideration is also required for patients who have severe renal impairment (kidney problems) or severe hepatic failure (liver problems).


Q: How soon after starting Aviatus should a person follow up with their doctor?

The medicine is intended only for short-term symptomatic use. Official guidelines state that if symptoms do not improve or persist after the maximum duration of seven days, the medicine should be discontinued, and a physician should be consulted.


Q: Is it safe to drive or operate machinery while on Aviatus?

Official warnings caution that the medicine can cause side effects such as drowsiness and vertigo (dizziness). Due to the possibility of these effects, caution is advised for individuals when driving or operating machinery.


How should Aviatus be stored and disposed of?

Storage and Stability

The medicine must be stored in its original bottle pack at a temperature not exceeding 30 C. The product must also be stored to protect from light to maintain its required stability.

For the oral solution form, the medicine has an in-use stability period and must be discarded after one month of opening.

Child Safety Storage

As a mandatory safety requirement, Aviatus must be kept strictly out of the sight and reach of children.

Official Disposal Rules

Unused or expired medicine must not be thrown away via wastewater or household waste. Disposal must follow the instructions provided by the pharmacist or local regulations for discarding medicines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Aviatus found in:

A-Z Index: